Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study
Publication date
2013
Authors
Warnier, M.J.
Blom, M.T.
Bardai, A.
Berdowski, J.
Souverein, P.C.
Hoes, A.W.
Rutten, F.H.
Boer, A. de
Koster, R.W.
Bruin, M.L. de
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
(c) UU Universiteit Utrecht, 2013
Abstract
Background: We aimed to determine whether (1) patients with obstructive pulmonary disease (OPD) have an increased risk
of sudden cardiac arrest (SCA) due to ventricular tachycardia or fibrillation (VT/VF), and (2) the SCA risk is mediated by
cardiovascular risk-profile and/or respiratory drug use.
Methods: A community-based case-control study was performed, with 1310 cases of SCA of the ARREST study and 5793
age, sex and SCA-date matched non-SCA controls from the PHARMO database. Only incident SCA cases, age older than 40
years, that resulted from unequivocal cardiac causes with electrocardiographic documentation of VT/VF were included.
Conditional logistic regression analysis was used to assess the association between SCA and OPD. Pre-specified subgroup
analyses were performed regarding age, sex, cardiovascular risk-profile, disease severity, and current use of respiratory
drugs.
Results: A higher risk of SCA was observed in patients with OPD (n = 190 cases [15%], 622 controls [11%]) than in those
without OPD (OR adjusted for cardiovascular risk-profile 1.4 [1.2–1.6]). In OPD patients with a high cardiovascular risk-profile
(OR 3.5 [2.7–4.4]) a higher risk of SCA was observed than in those with a low cardiovascular risk-profile (OR 1.3 [0.9–1.9]) The
observed SCA risk was highest among OPD patients who received short-acting b2-adrenoreceptor agonists (SABA) or
anticholinergics (AC) at the time of SCA (SABA OR: 3.9 [1.7–8.8], AC OR: 2.7 [1.5–4.8] compared to those without OPD).
Conclusions: OPD is associated with an increased observed risk of SCA. The most increased risk was observed in patients
with a high cardiovascular risk-profile, and in those who received SABA and, possibly, those who received AC at the time of
SCA.
Keywords
Econometric and Statistical Methods: General, Geneeskunde (GENK), Farmacie/Biofarmaceutische wetenschappen (FARM), Epidemiology, Farmacie(FARM), Geneeskunde(GENK), Medical sciences, Bescherming en bevordering van de menselijke gezondheid, Biomedische technologie en medicijnen, Ziekenhuisstructuur en organisatie van de gezondheidszorg, Public Health